GDF11 Biomarker and Therapy for Mood Disorders and Accelerated Aging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and diagnostic methods for mood disorders, including depression and bipolar disorder, as well as anxiety disorders, do not effectively address the accelerated aging and neurodegenerative effects associated with these conditions, and there is a need for new mechanisms to diagnose and treat these disorders.
Innovation Solution
Utilizing GDF11 as a biomarker and therapeutic agent, by detecting reduced levels of GDF11 in patients and administering GDF11 polypeptides or agonist antibodies to increase GDF11 levels, thereby treating or preventing mood and anxiety disorders and reversing accelerated aging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments and diagnostic methods are used for mood disorders, then existing standard care is provided, but accelerated aging and neurodegenerative effects are not effectively addressed
Solution Approach 1:
The patent applies universality by using GDF11 as a multi-functional tool that serves both diagnostic and therapeutic purposes. GDF11 levels are used to diagnose mood disorders and simultaneously administered as a treatment to address both the psychiatric symptoms and the accelerated aging effects, making a single substance perform multiple functions that traditional separate diagnostic and therapeutic approaches cannot achieve
Solution Approach 2:
The patent applies parameter changes by measuring and responding to GDF11 levels as a specific biomarker parameter. By detecting altered GDF11 levels in patients with mood disorders compared to healthy controls, the invention uses this parameter to guide treatment decisions and monitor therapeutic response, transforming a static diagnostic approach into a dynamic parameter-based treatment strategy
2Measurement precision
If new diagnostic mechanisms are developed to identify accelerated aging in mood disorder patients, then early intervention becomes possible, but diagnostic complexity increases
Solution Approach 1:
The patent applies the extraction principle by isolating and focusing on a single key biomarker, GDF11, from the complex array of potential aging markers. By extracting GDF11 as the specific diagnostic indicator for accelerated aging in mood disorders, the invention simplifies the diagnostic process while maintaining measurement precision, avoiding the need to simultaneously assess multiple complex biological parameters
3Reliability
If GDF11 levels are increased through administration of GDF11 polypeptides or agonist antibodies, then mood disorders and accelerated aging are treated, but treatment cost and complexity increase
Solution Approach 1:
The patent applies the intermediary principle by using GDF11 as a mediating substance that connects the treatment of mood disorders with the reversal of accelerated aging. Rather than using separate treatments for psychiatric symptoms and aging effects, GDF11 serves as an intermediary agent that simultaneously addresses both conditions, simplifying the overall treatment approach despite the advanced therapy modality
Data Source
Figure 1a~1e
Figure 1f~2a
Figure 2b~2e
AI summary
Provided are methods for the detection of GDF11 in a subject having or suspected of having a mood and/or anxiety disorder, comprising providing a sample from a subject having or suspected of having a mood and/or anxiety disorder; contacting the sample with a GDF11-binding molecule; and detecting bound GDF11. Also provided are methods of diagnosing or characterizing a mood and/or anxiety disorder in a subject, comprising providing a sample from a subject; contacting the sample with a GDF11-binding molecule; detecting bound GDF11; and comparing the levels of detected bound GDF11 to healthy reference levels. Also provided are methods of treating or preventing a mood and/or anxiety disorder and/or accelerated aging in a subject in need thereof, comprising administering to the subject an agent or composition which increases the levels of GDF11 polypeptide in the subject.